最新发布第5页
PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced-爱医学

PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced

WATCH TIME: 4 minutesWelcome to this special edition of Neurology News Network. I’m Marco Meglio.Newly announced analyses from the phase 2b PARADIGM trial showed that treatment wi...
CSF Anti-DAGLA Autoantibodies Identified as Potential Biomarker of Rapidly Progressive Cerebellitis-爱医学

CSF Anti-DAGLA Autoantibodies Identified as Potential Biomarker of Rapidly Progressive Cerebellitis

Kurt-Wolfram Sühs, MD(Credit: Hannover Medical School)In a small-scale study published in the Journal of Neurology, Neurosurgery & Psychiatry, investigators identified diacylglyce...
eason的头像-爱医学eason8个月前
200
Basal Ganglia Activity Associated With REM Sleep Behavior Disorder in Parkinson Disease-爱医学

Basal Ganglia Activity Associated With REM Sleep Behavior Disorder in Parkinson Disease

Jian-Guo Zhang, MD, PhD(Credit: Capital Medical University)Newly published in the Journal of Neurology, Neurosurgery and Psychiatry, findings showed that basal ganglia activities a...
eason的头像-爱医学eason8个月前
200
NeurologyLive® Brain Games: May 12, 2024-爱医学

NeurologyLive® Brain Games: May 12, 2024

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topi...
eason的头像-爱医学eason8个月前
240
Improvements in Neurological Assessments and Decreased Biological Age Seen With Alzheimer Agent Bezisterim-爱医学

Improvements in Neurological Assessments and Decreased Biological Age Seen With Alzheimer Agent Bezisterim

In a randomized, placebo-controlled trial, bezisterim (BioVie), an oral, small molecule, blood-brain permeable compound in development for Alzheimer disease (AD), demonstrated pote...
eason的头像-爱医学eason8个月前
220
Alkermes Initiates Phase 2 Vibrance-1 Trial of Narcolepsy Agent ALKS 2680-爱医学

Alkermes Initiates Phase 2 Vibrance-1 Trial of Narcolepsy Agent ALKS 2680

Craig Hopkinson, MD(Credit: LinkedIn)According to a recent announcement, Alkermes has initiated its randomized, double-blind, dose-range-finding, placebo-controlled phase 2 Vibranc...
eason的头像-爱医学eason8个月前
190
This Week on NeurologyLive® — May 13 2024-爱医学

This Week on NeurologyLive® — May 13 2024

Every week, the NeurologyLive® staff prepares this preview of what to expect from our coverage. This week on NeurologyLive®, there are a number of hot topics that we will be post...
eason的头像-爱医学eason8个月前
200
Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN-爱医学

Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN

WATCH TIME: 3 minutes'For many years, those of us who specialize in these disorders have seen patients with very similar features that the patients with Long COVID have. Many of th...
世界,您好!-爱医学

世界,您好!

欢迎使用 WordPress。这是您的第一篇文章。编辑或删除它,然后开始写作吧!
eason的头像-爱医学eason8个月前
21314
【丁香园】刷新纪录!未充分告知手术风险,患者起诉医院获赔 900 万-爱医学

【丁香园】刷新纪录!未充分告知手术风险,患者起诉医院获赔 900 万

本文作者:陈焰汐一起医疗事故,赔偿 902 万,是什么概念?近日,据 BMJ 报道,英国国家医疗服务体系 NHS 代下属医院对患者做出了约 100 万英镑(约合人民币 902 万元)的赔偿,刷新了 N
eason的头像-爱医学eason2年前
660